Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that has shown promising findings in a phase 2 clinical trial in patients with acute ischemic stroke (AIS). OBJECTIVE: To evaluate the efficacy and safety of rhPro-UK thrombolysis within 4.5 hours of symptom onset in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Haiqing, Wang, Yuan, Ma, Qingfeng, Feng, Wuwei, Liu, Rui, Lv, Xiaomei, Huang, Lijuan, Li, Yifan, Yang, Yi, Geng, Deqin, Zhu, Jianguo, Wei, Yan, Chen, Huisheng, Zhu, Runxiu, Zhai, Qijin, Guo, Jing, Liu, Bo, Zhao, Shigang, Wang, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370258/
https://www.ncbi.nlm.nih.gov/pubmed/37490291
http://dx.doi.org/10.1001/jamanetworkopen.2023.25415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370258/
https://www.ncbi.nlm.nih.gov/pubmed/37490291
http://dx.doi.org/10.1001/jamanetworkopen.2023.25415

Ejemplares similares